Previous 10 | Next 10 |
2023-04-04 04:38:40 ET Ophthalmology-focused bio-pharmaceutical company, OKYO Pharma ( NASDAQ: OKYO ) i ntends to delist from LSE or London Stock Exchange. The delisting will have no impact on the company’s ADSs which are traded on Nasdaq. The reason for delisti...
LONDON and NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (" OKYO " or the " Company "), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-...
LONDON and NEW YORK, March 29, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED“) to address the...
(NewsDirect) By David Willey, Benzinga Drug development isn’t known for being fast-paced, and developing any new drug is generally a long process. However, OKYO Pharma Ltd. (NASDAQ: OKYO) is moving quickly to develop its eye treatment drug, OK-101. It plans to begin trials for ...
2023-03-24 06:35:35 ET Okyo Pharma ( NASDAQ: OKYO ) said Panetta Partners, an entity in which the company's Executive Chairman Gabriele Cerrone has a beneficial interest, bought 10K ADSs at US$1.40 per ADS (American depositary shares). The ADSs would be equivalent to ...
LONDON and NEW YORK, March 24, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED“) to address the...
2023-03-16 10:19:06 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Okyo Pharma (NASDAQ: OKYO ) stock is on the rise Thursday as investors react to news about its Phase 2 clinical trial of OK-101 . OK-101 is the company’s drug can...
2023-03-16 09:33:00 ET When searching for penny stocks to buy or penny stocks to watch, it’s good to focus on catalysts. Typically valued under $5 per share, these stocks generally attract small and new investors. Even with the glitz and glamour that comes with massive breakouts,...
LONDON and NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today ann...
2023-03-14 09:54:11 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Uber (NYSE: UBER ) stock and Lyft (NASDAQ: LYFT ) stock are on the rise Tuesday after a court ruled that the companies’ drivers are contractors . ...
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...